# MaxCyte, Inc. (MXCT) · Edgar & Edgarette company card

> MaxCyte, Inc. (MXCT) saw revenue fall 14.5% in FY2025 to $33 million, operating margin -157% against a 14.9% median for commercial physical & biological research, equity 84.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1287098 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/MXCT) · [JSON](https://www.pops4.com/boards/company/MXCT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $33M |
| Revenue growth, 1 year | -14.5% |
| Revenue growth per year | -0.6% |
| Operating margin | -157.1% (prior year -132.5%) |
| Net margin | -135.1% |
| Operating cash flow | −$34M |
| Capital spending | $2M |
| Free cash flow | −$36M |
| Cash | $20M |
| Long-term debt | — |
| Total assets | $203M |
| Total equity | $171M |
| Equity ÷ assets | 84.7% |
| Return on equity | -26.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 3.25 (safe zone)
- Piotroski F: 3 of 9 (middling)
- Beneish M: -2.73 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -157.1% in FY2025; revenue is hard to predict: its 80% range is ±43%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $33.0M (FY2025). Experience: revenue down 14.5% on the year, down 0.6% a year over 4 years; operating margin -157.1%, down from -132.5%. Soundness: equity 84.7% of assets, return on equity -26.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $17.9M and $45.3M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $16.8M to $48.3M. A statistical range, not company guidance. Against peers (8 filers, $50M+ revenue, its industry group): operating margin -157.1% against a 14.9% median; growth -14.5% against 5.2%.

Range logged 2026-11-01, receipt fdc489aca297b198, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-06-16 ([filing](https://www.sec.gov/Archives/edgar/data/1287098/000110465926074594/0001104659-26-074594-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-03-27 ([filing](https://www.sec.gov/Archives/edgar/data/1287098/000110465926036201/0001104659-26-036201-index.htm))

## Recent filings

- 10-Q · filed 2026-11-10 · [filing](https://www.sec.gov/Archives/edgar/data/1287098/000110465926125236/0001104659-26-125236-index.htm)
- 8-K · filed 2026-11-10 · 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1287098/000110465926124829/0001104659-26-124829-index.htm)
- 8-K · filed 2026-10-14 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1287098/000110465926115745/0001104659-26-115745-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1287098/000110465926095971/0001104659-26-095971-index.htm)
- 8-K · filed 2026-08-12 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1287098/000110465926094886/0001104659-26-094886-index.htm)
- 8-K · filed 2026-06-17 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1287098/000110465926075211/0001104659-26-075211-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001287098.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1287098

## Cite

POPS4, Edgar & Edgarette: MaxCyte, Inc. (MXCT) company card, from the company's own SEC filings, accessed 2026-11-11, https://www.pops4.com/boards/company/MXCT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.